CCR8在肿瘤免疫治疗中的研究进展

Research progress of CCR8 in tumor immunotherapy

目前针对肿瘤的治疗方法不断进步,免疫治疗已成为遏制肿瘤进展的有效手段。但目前的免疫治疗仍有局限性,只有较少的一部分特定患者可以从免疫治疗中完全获益。由于复杂的肿瘤微环境取决于不同的个体,所以免疫靶向药物在不同的肿瘤微环境中会受到不同程度的免疫抑制,从而无法发挥全部作用。在肿瘤微环境中,调节性T(regulatory T,Treg)细胞起到免疫抑制的作用,在许多瘤种中Treg细胞大量浸润从而造成肿瘤组织的免疫逃逸,会对治疗和预后产生不良影响。CC族趋化因子受体8(CC chemokine receptor 8,CCR8)属于CC族趋化因子受体家族,其主要在肿瘤微环境中的Treg细胞上特异性高表达,而在周围正常组织和外周血中低表达,因此CCR8可以作为Treg细胞的一种特异性标志物,是一种有潜力的治疗靶点和生物标志物。本文对近年来CCR8在不同瘤种中的研究进展进行了归纳和总结,以期为后续研究提供参考。

Therapies for tumors continue to develop,and tumor immunotherapy has emerged as an effective means of controlling tumor progression.Given the limitations of immunotherapy,only some specific patients can benefit from immunotherapy.Since the complex tumor microenvironment is highly influenced by individual variability,immunotherapy will be subjected to different degrees of immune suppression in different tumor microenvironments and thus cannot exert its full effect.In the tumor microenvironment,regulatory T(Treg)cell plays as an immunosuppressive role.Numerous Treg cells infiltrate in indifferent tumor types,resulting in immune escape of tumor tissues,which will have a negative impact on treatment and prognosis.CC chemokine receptor 8(CCR8)belongs to the CC chemokine receptor family.CCR8 is specifically expressed on Treg cell in the tumor microenvironment and expressed at low level in the surrounding normal tissues and peripheral blood thus it can be a specific marker for Treg cell.CCR8 is a potential therapeutic target and biomarker.This review summarized the research progress of CCR8 in different tumor types in recent years,so as to provide reference for subsequent research.